Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)

J2T-DM-KGAE -

The study will assess the safety and efficacy of lebrikizumab in adolescent participants with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

Trial Summary

Age Range
12 - 17 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
No
Enrollment Goal
206
Trial Dates
Feb 11, 2020 - Jun 22, 2022
How long will I be in the trial?
The study will last about 52 weeks and may include up to 18 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have atopic dermatitis that has been present for at least one year

  • Participants must have had an inadequate response to topical medications (medications applied to the skin)

Participants Must Not:

  • Participants must not have received a vaccine within 12 weeks of starting the study

  • Participants must not have hepatitis

  • Participants must not have a history of HIV

  • Participants must not have a history of cancer within 5 years

  • Women must not be pregnant, breastfeeding or plan to become pregnant during the study

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.